Psychopharmacological treatment
Phase 3Small molecule
Psychopharmacological treatment is one of 35 small molecule programs targeting Depression. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
44 competitors in Depression
#DrugCompanyPhaseTrials
1Cymbalta
Jazz PharmaceuticalsApproved
Ketalar
AAultman Health Foundation
Approved
Brintellix
TakedaApproved
Zoloft
VViatris Specialty LLC
Approved
Vraylar
AbbVieApproved
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Wellbutrin
GGlaxo Dba Glaxosmithkline
Approved
Estrace
Novo NordiskApproved
Spravato
WWim Janssens
Approved
Risperdal
WWim Janssens
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- GGoethe University